Business
CARsgen Announced 2024 Annual Results
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.
About this update from Carsgen Therapeutics Holdings Ltd.
[{"type":"text","content":"SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.","length":201,"tagName":"p"},{"type":"text","content":"Business Highlights","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Zevor-cel was approved by China's National Medical Products Administration (NMPA).","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"As of December 31, 2024, certification and filings for zevor-cel completed in 23 provinces or cities, covering over 200 healthcare institutes; CARsgen has received a total of 154 valid orders from its commercialization partner Huadong Medicine.","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"Satri-cel ST-01 confirmatory Phase II trial for gastric cancer in China: enrollment has been completed, and the study has met its primary endpoint. Satri-cel received BTD designation from CDE of China NMPA. CARsgen plans to submit a New Drug Application (NDA) to the China NMPA during the first half of 2025.","length":308,"tagName":"p"}]},{"val":[{"type":"text","content":"Results from the investigator-initiated trial (IIT) of satri-cel were published in Nature Medicine and at the 2024 ASCO Annual Meeting.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"The results of the IIT of an allogeneic BCMA-targeting CAR-T product CT0590, which deploys the THANK-uCAR® technology platform, were presented at the 2024 ASH Annual Meeting.","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Developed THANK-u Plus™ platform as an enhanced version of THANK-uCAR® allogeneic CAR-T platform. Multiple allogeneic CAR-T products in development, covering treatment areas such as hematologic malignancies, solid tumors, and autoimmune diseases.","length":251,"tagName":"p"}]},{"val":[{"type":"text","content":"Introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-T development in mainland China.","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and bank balances were around RMB1,479 million as of December 31, 2024. Cash and cash equivalents and deposits at the end of 2025 are expected to be not less than RMB1,080 million. Expect to have adequate cash into the 2028.","length":22...